Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Comparison of the efficacy, safety, and onset of action of mizolastine, cetirizine, and placebo in the management of seasonal allergic rhinoconjunctivitis
Autore:
Sabbah, A; Daele, J; Wade, AG; Ben-Soussen, P; Attali, P;
Indirizzi:
CHU Angers, Lab Explorat Fonct Allergol, F-49033 Angers 01, France CHU Angers Angers France 01 at Fonct Allergol, F-49033 Angers 01, France Hop Citadelle, Liege, Belgium Hop Citadelle Liege BelgiumHop Citadelle, Liege, Belgium Clydebank Hlth Ctr, Glasgow, Lanark, Scotland Clydebank Hlth Ctr Glasgow Lanark Scotland tr, Glasgow, Lanark, Scotland Synthelabo Rech, Bagneux, France Synthelabo Rech Bagneux FranceSynthelabo Rech, Bagneux, France
Titolo Testata:
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
fascicolo: 4, volume: 83, anno: 1999,
pagine: 319 - 325
SICI:
1081-1206(199910)83:4<319:COTESA>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
RHINITIS; ANTIHISTAMINE; TERFENADINE; LORATADINE; ASTEMIZOLE; THERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Sabbah, A CHU Angers, Lab Explorat Fonct Allergol, 4 Rue Larrey, F-49033 Angers 01, France CHU Angers 4 Rue Larrey Angers France 01 9033 Angers 01, France
Citazione:
A. Sabbah et al., "Comparison of the efficacy, safety, and onset of action of mizolastine, cetirizine, and placebo in the management of seasonal allergic rhinoconjunctivitis", ANN ALLER A, 83(4), 1999, pp. 319-325

Abstract

Background: Mizolastine is a potent and selective H-1-receptor antagonist with additional anti-allergic properties. Objective: The aim of this European multicenter, randomized, double-blind study was to compare the efficacy of mizolastine 10 mg (n = 122), cetirizine 10 mg (n = 125), and placebo (n = 128) once daily for 28 days in patientswith seasonal allergic rhinoconjunctivitis (SAR), with focus on the onset of action. Methods: Symptoms were evaluated by the investigator using a total symptomscore (TS) and by the patient (first week). Responders (R) were patients with a TS decrease of at least 50%. Safety was assessed according to the spontaneous reporting of adverse events. Results: Both mizolastine and cetirizine were effective in relieving the symptoms of SAR. After 7 days of treatment, the improvement in TS and responder's rate were significantly (P <.05) greater in patients treated with mizolastine (TS change versus baseline, mean +/- SD: -6.40 +/- 5.71; R: 55%) and cetirizine (TS change versus baseline: -6.24 +/- 5.24; R: 53%) than withplacebo (TS change versus baseline: -4.11 +/- 5.91; R: 40%). Both drugs acted rapidly, within 2 hours of the first intake. During the first 3 days, mizolastine relieved symptoms more effectively than cetirizine, the difference being significant on the second (P =.027) and third (P =.050) day. Both mizolastine and cetirizine were well tolerated. Conclusion: Mizolastine 10 mg once daily is at least as effective as cetirizine in relieving symptoms of SAR, onset of action is rapid with clinical effect evident within 2 hours.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/09/18 alle ore 08:12:58